Researchers at the Icahn School of Medicine at Mount Sinai have identified 53 drugs approved for use in treating depression, cancer, heart disease, and other illnesses that may also be effective in fighting the Ebola virus. The findings appeared online in the December 17, 2014, journal Emerging Microbes & Infections. Read more
Seminal research led by James Ferrara, MD, DSc, Ward-Coleman Chair in Cancer Medicine, has produced a promising approach to treating patients with graft-versus-host disease (GVHD)—a sometimes fatal complication of bone marrow transplantation in which the donor’s immune cells attack the recipient’s body. Bone marrow transplants are often used to treat patients with leukemia, lymphoma, and other blood diseases. Read more
What are statins?
Statins are a class of cholesterol lowering medication therapies that have been extensively evaluated in controlled clinical trial studies. These medications have been consistently shown to reduce the risk of a first cardiovascular event including heart attack, stroke, and death from heart disease. Also, the drugs can reduce recurrent (two or more) cardiovascular events in people with a prior heart attack, or other acute coronary syndromes that result from a reduction in blood flow to the heart muscle, or stroke. In addition, studies show statins have helped reduce the total amount of deaths worldwide overall from cardiovascular diseases. Read more
For the first time in its 47-year history, the Crohn’s & Colitis Foundation of America has awarded all three of its 2014 annual scientific achievement awards to research and academic luminaries at the Mount Sinai Health System. Read more
“We have learned that the impossible is possible, and advances are being made that we could not have imagined just a few years ago,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System, at the conclusion of the school’s third annual SinaInnovations conference in November.
The conference, which took place on campus Tuesday and Wednesday, November 18 and 19, respectively, focused on breakthroughs in medicine and engineering that improve human health and was sponsored jointly with Mount Sinai’s academic affiliate Rensselaer Polytechnic Institute (RPI).
Researchers at the Icahn School of Medicine at Mount Sinai have received more than $31 million from the National Institutes of Health (NIH) to create three new centers that will study how drugs interact with human cells to increase their effectiveness and decrease side effects.
A new Drug Toxicity Signature Center will be run by Ravi Iyengar, PhD, Dorothy H. and Lewis Rosenstiel Professor, Department of Pharmacology and Systems Therapeutics, who has received a grant totaling $11.6 million from the NIH. By leveraging the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System database, the center will develop cell signatures that can be used to predict the effects of certain drugs and drug combinations.
Developing new drugs for the treatment of sarcoidosis isn’t easy. First, the cause of sarcoidosis is unknown. Second, prednisone, a remarkably effective medication for the treatment of sarcoidosis, limited only by its adverse side effect profile, is tough to beat. Third, sarcoidosis is a rare disease, which affects fewer than 200,000 people in the US per year. These challenges notwithstanding, researchers at Mount Sinai will be testing a new drug for the treatment of sarcoidosis. In late 2015, the Division of Pulmonary, Critical Care and Sleep Medicine will be enrolling sarcoidosis patients, who meet prespecified entry criteria, into a clinical trial to evaluate the efficacy and safety of KiactaTM for the treatment of sarcoidosis.
Abnormalities in the structure and function of the brain can appear in people who are overweight, smoke, have diabetes, hypertension, elevated lipids, or metabolic syndrome before the other consequences of vascular risk factors—such as a heart attack or stroke—appear, according to a team of researchers at Icahn School of Medicine at Mount Sinai.
A pioneering study now under way at the Mount Sinai Health System’s Translational and Molecular Imaging Institute is exploring why older patients often wake up from surgery disoriented and some experience cognitive deficits several months later. The study is being led by Jeffrey Silverstein, MD, Professor and Vice Chair for Research in the Department of Anesthesiology at Icahn School of Medicine at Mount Sinai, with $3.1 million in funding from The National Institute on Aging.